Block Listing Review, Application and TVR

RNS Number : 5573K

ReNeuron Group plc

02 September 2021

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review, Block Listing Application

and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

Name:	ReNeuron Group plc
Name of Scheme:	ReNeuron Share Option Schemes
Period of Return:	From 1 March 2021 to 31 August 2021
Balance of unallotted securities under scheme(s) from previous return:	663,687 Ordinary Shares (of 1p each)
Plus : The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):	N/A
Less : Number of securities issued/allotted under scheme(s) during period	80,697
Equals : Balance under scheme(s) not yet issued/allotted at end of period:	582,990 Ordinary Shares
Number and class of securities originally admitted and the date of admission:	20,000 ordinary shares on 13 May 2010

Block Listing Application

Given the number of options under the existing Share Option Scheme, the Company announces that it has made an application to the London Stock Exchange for a block listing of 3,000,000 additional new ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") to be admitted to AIM.

The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company.

When issued, the Ordinary Shares under this block listing will rank pari passu with the Company's existing issued Ordinary Shares. It is expected that admission will be effective on 3 September 2021.

Total Voting Rights

At 31 August 2021, the Company had 56,936,402 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 56,936,402 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

ReNeuron	www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer	Via Walbrook PR
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	[phone]
Allenby Capital Limited (Joint Broker)	[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus, Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 

END

 

 

TVREAENAESAFEFA